China Pediatric Pharm. Inc. (fka CPDU)

[Renee]

CPDU registration revoked:

https://www.sec.gov/litigation/admin/2019/34-86243.pdf

[Renee]

CPDU SEC Suspension for severely delinquent Financials:

https://www.sec.gov/litigation/suspensions/2017/34-81490.pdf

Order:

https://www.sec.gov/litigation/suspensions/2017/34-81490-o.pdf

Admin Proceeding:

https://www.sec.gov/litigation/admin/2017/34-81489.pdf

[dffhogs]

10Q out:

http://www.sec.gov/Archives/edgar/data/1354071/000112785510000099/chinapedpharm10q093009.htm

[db7]

China Pediatric Pharmaceuticals, Inc. Closes $1.5 Million Private Placement Transaction



Buzz up! 0 Print..Press Release Source: China Pediatric Pharmaceuticals, Inc. On Thursday February 11, 2010, 7:11 am EST
XI’AN, China--(BUSINESS WIRE)--China Pediatric Pharmaceuticals, Inc. (OTC Bulletin Board: CPDU) ("China Pediatric Pharmaceuticals " or the "Company"), today announced it has recently closed a private placement financing. In the transaction the Company issued 375,000 shares of the Company's common stock at a price of $4.00 per share for an aggregate purchase price of $1.5 million.

The Company plans to use the proceeds of the Regulation S private placement for general corporate purposes such as working capital.

"We are glad to see the swift and successful closing of the recent private placement transaction and the support from several investors. The proceeds will strengthen our balance sheet and help us expand our operations capacity as we continue to strive to become the #1 brand of pediatric medicines in China," said Mr. Jun Xia, Chairman and Chief Executive Officer of China Pediatric Pharmaceuticals. "We thank all of our new investors for their support in helping us reach our long term goals."

About China Pediatric Pharmaceuticals, Inc.

China Pediatric Pharmaceuticals, Inc. has its headquarters in Xi’an, Shaanxi Province, China. The Company identifies, discovers, develops manufactures and distributes both prescription and over-the counter, including both conventional and Traditional Chinese Medicines (“TCMs”), pharmaceutical products for the treatment of some of the most common ailments and diseases, with pediatric medicine as its focus. China Pediatric Pharmaceuticals, Inc.’s manufacturing facility located in Baoji City, Shaanxi Province. The Company distributes its high value, branded medicines, both prescription and OTC, through exclusive territory agents who sell our products directly to local pharmacies who in turn sell them to their retail customers. For the nine months ended September 30, 2009, Revenue was $ 11,323,143 and Net Income was $ 2,583,391 or $0.31 per share. As at September 30, 2009, Shareholders’ Equity was $ 11,613,667 and Total Assets were $ 15,164,459. For more information go to: www.jialipharma.com

For more information, please contact:

China Pediatric Pharmaceuticals, Inc.

Mr. Jun Xia, Chief Executive Officer

Mr. Minggang Xiao, Chief Financial Officer

Ms. Vivian Juan Wei, Vice President, Corporate Affairs

9th Floor, No. 29 Nanxin Street,

Xi’an, Shaanxi Province, P.R.C., 710004

Phone: [phone]

Email: [e-mail]

Website: www.jialipharma.com

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the company's ability to raise additional capital to finance the company's activities; the effectiveness, profitability, and the marketability of its products; legal and regulatory risks associated with the share exchange; the future trading of the common stock of the company; the ability of the company to operate as a public company; the period of time for which its current liquidity will enable the company to fund its operations; the company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; the company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the company's filings with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the companies and the industry. The company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.


Contact:
China Pediatric Pharmaceuticals, Inc.Mr. Jun Xia, Chief Executive OfficerMr. Minggang Xiao, Chief Financial OfficerMs. Vivian Juan Wei, Vice President, Corporate Affairs9th Floor, No. 29 Nanxin Street,Xi’an, Shaanxi Province, P.R.C., 710004Phone: [phone]Email: [e-mail]: www.jialipharma.com

[dffhogs]

Form S-1, filed jan. 28th....

http://www.sec.gov/Archives/edgar/data/1354071/000112785510000020/cpps1.htm

[db7]

yep.. i was able to sell all my shares $4ish and have been on the bid trying to rebuy... only action has been people buying my shares

[erpy]

Is this stock still trading at all? I looked under CPDU but it never trades? What is going on? Usually reverse split happens within one trading day.. What is going on with company and this stock?

[db7]

China Pediatric Pharmaceuticals, Inc. Files Application for NASDAQ Listing




China Pediatric Pharmaceuticals, Inc. (OTC Bulletin Board: CPDU) ("China Pediatric Pharmaceuticals " or the "Company"), today announced it has applied for listing approval on the NASDAQ Capital Market (“NASDAQ”)

“This is an important milestone for China Pediatric Pharmaceuticals, and we are committed to working with NASDAQ to fulfill all of its listing requirements,” said Mr. Jun Xia, Chairman and Chief Executive Officer. “As a senior exchange NASDAQ is well suited for high-growth companies such as China Pediatric Pharmaceuticals that meet its stringent listing requirements. With a NASDAQ listing, our visibility will increase among investors who follow companies like ours, improving trading volume and liquidity. This should, in turn, attract new investors to our Company.” The application is subject to review by NASDAQ's Listing Qualifications Department for compliance with all NASDAQ Capital Market requirements. The Company's common stock will continue to trade on the OTC Bulletin Board under its current symbol, CPDU, until the Company is notified of its acceptance. CPDU believes it satisfies all of the listing qualifications associated with this application. We hope to receive approval to list on NASDAQ within two to three months

About China Pediatric Pharmaceuticals, Inc. China Pediatric Pharmaceuticals, Inc. has its headquarters in Xi’an, Shaanxi Province, China. The Company identifies, discovers, develops manufactures and distributes both prescription and over-the counter, including both conventional and Traditional Chinese Medicines (“TCMs”), pharmaceutical products for the treatment of some of the most common ailments and diseases, with pediatric medicine as its focus. China Pediatric Pharmaceuticals, Inc.’s manufacturing facility located in Baoji City, Shaanxi Province. The Company distributes its high value, branded medicines, both prescription and OTC, through exclusive territory agents who sell our products directly to local pharmacies who in turn sell them to their retail customers. For the nine months ended September 30, 2009, Revenue was $ 11,323,143 and Net Income was $ 2,583,391 or $0.31 per share. As at September 30, 2009, Shareholders’ Equity was $ 11,613,667 and Total Assets were $ 15,164,459. For more information go to: www.jialipharma.com For more information, please contact: China Pediatric Pharmaceuticals, Inc

Mr. Jun Xia, Chief Executive Officer Mr. Minggang Xiao, Chief Financial Officer Ms. Vivian Juan Wei, Vice President, Corporate Affairs 9th Floor, No. 29 Nanxin Street, Xi’an, Shaanxi Province, P.R.C., 710004 Phone: [phone] Email: [e-mail] Website: www.jialipharma.com Safe Harbor Statement This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the company's ability to raise additional capital to finance the company's activities; the effectiveness, profitability, and the marketability of its products; legal and regulatory risks associated with the share exchange; the future trading of the common stock of the company; the ability of the company to operate as a public company; the period of time for which its current liquidity will enable the company to fund its operations; the company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; the company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the company's filings with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the companies and the industry. The company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results

[db7]

2 for 7 split... now just waiting on mm's to show up and action to start

[erpy]

What happeneded to this stock?

[db7]

CPDU on Monday

[dffhogs]

I was wondering if anyone noticed....


Thanks for the breakdown.

[2morrowsGains]

NICE Q3 results based on info in Friday's Form 8K/A filing...

- Q3 Net Income = approx $998k = Approx $0.12 EPS.

- Forward PE = 3.6 based on current $1.74 share price (and it's been trading lower).

- NICE increase in Cash & Equivalents...$2.8M (Q/E 9/30/09) UP from $800k (Q/E 6/30/09)...
As of June 30, 2009, we had cash and cash equivalents of approximately $0.8 million.
As of September 30, 2009, we had cash and cash equivalents of approximately $2.8 million.

- A/R is down from $5.1M (Q/E 6/30/09) to $3.9M (Q/E 9/30/09).

- NO long term debt with total liabilites of ONLY $3.6M.

- Paying taxes.

- Net cash provided in operating activities for the six months ended June 30, 2009 was $14,078.
Net cash generated in operating activities for the nine months ended September 30, 2009 was $1,565,534.

- LOW share count ...

"These pro forma financial statements assume the Exchange Transaction occurred as of the beginning of the period ending June 30, 2009. Therefore, the weighted average number of shares outstanding for the period ending June 30, 2009 equals the total number of shares outstanding upon completion of the Exchange Transaction as follows:

Pre-Exchange Transaction Common Shares Outstanding:     9,300,000    
  Re-purchase of the Company’s shares:     (5,000,000 )  
  Reverse stock split (7 pre-shares for 2 post-shares):     (3,071,429 )  
  Issuance of the Company’s shares for all outstanding shares of China Children:     7,000,000    
  Post-Exchange Transaction Common Shares Outstanding:     8,228,571

Note that the potentially issuable shares of common stock underlying warrants have been excluded from the weighted average number of shares outstanding in the calculation of basic and diluted earnings per share as application of the treasury stock method would result in the assumed exercise of warrants being anti-dilutive."

RE Warrants...

There are approx 2.5M warrants outstanding. "Assuming the exercise of the Warrants, as of September 30, 2009, we have 10,728,571 shares of common stock outstanding."

"Each Warrant and piggy-back warrant entitles the holder to purchase one share of our Common Stock. The Warrants will be exercisable, in whole or in part, at an exercise price equal to $3.00 per share (“Exercise Price”). The Piggyback Warrants will be exercisable, in whole or in part, at an exercise price equal to $5.00 per share (“Exercise Price”). The Warrants may be exercised at any time upon the election of the Investor, beginning on the date of issuance and ending of the second anniversary of the closing of the Share Exchange Agreement. The Piggy-back Warrants may be exercised at any time upon the election of the Investor, beginning on the date of issuance and ending of the third anniversary of the closing of the Share Exchange Agreement."
(page 40)
http://sec.gov/Archives/edgar/data/1354071/000112785509000513/lidhair8ka2100609.htm

Waiting on the symbol change which should draw more attention to the company...

- "On the effective date of the merger, the Company’s name was changed to “China Pediatric Pharmaceuticals, Inc.” and the Company’s Articles of Incorporation were amended to reflect this name change.
Following the Combination, the combined Company will continue to be traded on the OTCBB, under the symbol “LHSI”, however we will request a new symbol closer in form to China Pediatric Pharmaceuticals, Inc."
http://finance.yahoo.com/news/OTCBB-LHSI-Completes-Name-bw-610709196.html?x=0&.v=2

LHSI could be a nice Chinese sleeper stock.

All notes are my opinion based on LHSI's 11/27/09 8-K/A filing and should be re-checked.

[dffhogs]

Amended the 8K

http://www.sec.gov/Archives/edgar/data/1354071/000112785509000513/lidhair8ka2100609.htm

[dffhogs]

Up 28%.....showing a little life

[db7]

thanks for the update

[dffhogs]

NT 10Q filed today.

[db7]

yep.. i wanted to avg down.. guess i CAN'T

[steeledge]

I just love it when they take it upon themselves to protect us from profits.

[db7]

calling in won't even help with this message.... tda is only allowing sells

[db7]

yep through tda.. i'm pretty sure that message means you cannot even buy on the phone with them

[steeledge]

lol - seems like AMTD does that on a lot of the stocks i buy, after i buy them. same deal with HMDI...now i have to call in.

[dffhogs]

problem buying?

[db7]

this can't be good, "Opening transactions for this security are not accepted."

[steeledge]

Here's the condensed one:
* .19 EPS for 1st 6 months of the year.
* Only Chinese pediatric play
* New symbol coming
* Uplist coming


That's all i need to know. :^)

I'll have to buy some more at 1.75 when i free up some cash.

[dffhogs]

I have tried to read the 8K for the third time.....I am still less than half way through it....lol

Anyone have the condensed version?

[steeledge]

Uh oh, the Lid is off this stock for now. 1.72x2.00 now

[steeledge]

How about "China Lid Hair Studios Shanghai" lol

[2morrowsGains]

Just need to get the name 'Lid Hair Studios International, Inc' out of the picture and hopefully this company is going to get more attention.

[steeledge]

I agree entirely. It always amazes me when there are shares for sale in a situation like this. Right now we're somewhat fortunate that there's a seller at every nickel for about 25k shares. Without him/her, there'd be no shares available. That said, who is selling? Presumably these are some reverse-merger shares.

I remain quite excited about this one due to the niche, and hope that shares remain to be bought for some time yet.

[2morrowsGains]

LHSI...Could be a nice Chinese sleeper. The name of the company and symbol has not yet been changed to reflect the R/M so you have to look at the recent 8k filing to get the skinny.
Last year Shaanxi Jiali Pharmaceuticals had a 25% increase in net income in the 2nd half of the year over the first half. (China pharma sales tend to be stronger in the 2nd half of the year). They had EPS of $0.19 in the first half of this year., so if they can crack out another 25% HoH increase, we'd be looking at approx $0.24 in the 2nd half of this year, or $0.43 EPS for FY2009. Based on todays stock price of $1.75, that would equal a PE of 4.
So I'm thinking when they finalize the name and symbol change, LHSI could get some attention, especially if the stock price is still below $2. And it's nice to see that they are already looking to uplist from here...

"Our next goal will be to seek a listing on a senior stock exchange in the United States."
http://finance.yahoo.com/news/OTCBB-LHSI-Completes-Reverse-bw-1190664794.html?x=0&.v=1

More from the 8k...

As of September 30, 2009, an aggregate of 8,228571 shares of Common Stock were outstanding, including shares issued pursuant to the Closing.

LIQUIDITY AND CAPITAL RESOURCES
As of March 31, 2009, we had cash and cash equivalents of approximately $1.2 million. We believe our existing cash and cash equivalents will be sufficient to maintain our operations at present level for at least the next twelve months. We plan to review acquisition opportunities as a strategy for further growth.
Total liabilities approx $3M.
http://sec.gov/Archives/edgar/data/1354071/000112785509000447/lidhair8ka100609.htm

[nsomniyak]

Not only a symbol with "C" for China in it, but having the new corporate name show up on Yahoo, ameritrade, etc. will really help.

Lid Hair Studios International not only does not convey a China medial stock, it sounds like a "fad" stock and one that would be shorted based on name only.

[steeledge]

Not only the 'C', but also the uplist!

[nsomniyak]

OK - I'm in. Hated to chase it, but I figure when they get a symbol starting with "C" it will be good for visibility and maybe another 25% :)